Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06922669 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Publications: details revised at 4 of 5 entriesv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2025 to Jun 24, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Herein, a multicenter randomized controlled trial (RCT) has been designed to explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia.
Trial Details
NCT Number NCT06922669
Lead Sponsor General Hospital of Shenyang Military Region
Conditions
(from sponsor)		 Drug Induced Liver Injury
Related terms Chemical and Drug Induced Liver Injury, Hyperbilirubinemia, Liver Failure
Enrollment 232 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov